Hubei Shu Bang Pharma Co., Ltd. romanized
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference bdf207c586
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/13 06:42.
Drug filings
8 acceptance records as first applicant, grouped into 5 source drug names. Source data as of 2026/11/13 06:42.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
Minoxidil Liniment 2 records · Latest accepted 2025/10/30
Supplement · 2
甲硝唑凝胶 · No verified English name 1 records · Latest accepted 2025/03/04
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2500906 | Generic | 2025/03/04 | Hubei Shu Bang Pharma Co., Ltd. romanized | CDE ↗ |
盐酸阿莫罗芬搽剂 · No verified English name 2 records · Latest accepted 2024/08/08
Generic · 2
Finasteride Tablets 1 records · Latest accepted 2024/08/03
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2401189 | Supplement | 2024/08/03 | Hubei Shu Bang Pharma Co., Ltd. romanized | CDE ↗ |
Minoxidil Topical Solution 2 records · Latest accepted 2023/03/07
Generic · 2
Changes in the last 90 days
0 events from 2026/08/16 to 2026/11/13. CDE data as of 2026/11/13 06:42; NMPA data as of 2026/11/12 18:32.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
- No matching records were found in the currently loaded source data; coverage dates are listed below.
Under review
0 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/13 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
Catalogue holder records
4 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/13 06:39. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | Approval number | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Finasteride Tablets | Hubei Shu Bang Pharma Co., Ltd. romanized | Hubei Shu Bang Pharma Co., Ltd. romanized | 国药准字H20258223 | 2025/10/14 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| 尼美舒利分散片 · No verified English name | Hubei Shu Bang Pharma Co., Ltd. romanized | Hubei Shu Bang Pharma Co., Ltd. romanized | 国药准字H20010730 | 2021/08/19 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| 尼美舒利分散片 · No verified English name | Hubei Shu Bang Pharma Co., Ltd. romanized | Hubei Shu Bang Pharma Co., Ltd. romanized | 国药准字H20010734 | 2021/08/19 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Lafutidine Tablets | Hubei Shu Bang Pharma Co., Ltd. romanized | Hubei Shu Bang Pharma Co., Ltd. romanized | 国药准字H20213645 | 2021/08/18 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
0 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/13 06:41.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
1 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/13 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Telmisartan and Hydrochlorothiazide Tablets | CYHB2201443 | Supplement | 2022/08/17 | Yuan Da Pharmaceuticals (Zhongguo) Co., Ltd. romanized; Hubei Shu Bang Pharma Co., Ltd. romanized | CDE ↗ |
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/13 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/13 06:39
- Full API register
- Last successful update: 2026/11/13 06:41
- NMPA drug delivery notices
- Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.